Organogenesis Q4 revenue up 27% to $126.7M; net income $7.7M vs loss year ago; guides FY25 rev $480-535M

Organogenesis Holdings Inc.

2024-FY EPS reported -$0.01 revenue$482,043,000

Q4 net revenue $126.7M (+27%); Advanced Wound Care $118.6M (+27%), Surgical/Sports $8.1M (+24%).
Q4 net income $7.7M ($0.05 diluted EPS) vs net loss $0.6M; adjusted net income $8.8M vs $1.9M.
FY24 revenue $482.0M (+11%); net income $0.9M vs $4.9M; adjusted net income $20.5M vs $12.7M.
Cash $136.2M, zero debt (vs $104.3M cash and $66.2M net debt year-end 2023).
FY25 guidance: revenue $480-535M; net income $9.5-38.8M; Adj. EBITDA $43.6-83.2M; ReNu BLA submission targeted by year-end.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.